Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01279083 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

A Phase 1 study, sponsored by Santen.

Completed
Registry status
Phase 1
Development phase
147
Enrollment target

NCT01279083 is a Phase 1 study that has completed, run by Santen. The registered enrollment target is 147 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01279083, a Phase 1 study, has completed, sponsored by Santen.

COMPLETED
Registry status
Phase 1
Development phase
147 participants
Enrollment target

Study Summary

To investigate the safety and efficacy of DE-112 in lowering intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.

Interventions

  • DRUG DE-112
  • DRUG DE-112 Vehicle Solution

Trial Details

FieldValue
Enrollment Target 147 participants
Start Date 2011-01
Est. Completion 2012-02
Phase Phase 1

Sponsor

Santen

32 total trials

What the Registry Record Tells You About NCT01279083

The ClinicalTrials.gov registry entry for NCT01279083 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Santen, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which DE-112 is the first listed.

NCT01279083 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01279083 about?

NCT01279083 is a clinical study titled "Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension". To investigate the safety and efficacy of DE-112 in lowering intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.

What is the current status of trial NCT01279083?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2011-01. Estimated completion is 2012-02.

What interventions are being tested in trial NCT01279083?

The interventions under investigation include: DE-112 (DRUG), DE-112 Vehicle Solution (DRUG).

Who is sponsoring clinical trial NCT01279083?

This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.